Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a cancer medicine in the pipeline would inhibit production of a protein that may interfere with the effectiveness of chemotherapy.

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • The increase in the stock of cancer drugs from 1975 to 1995 accounted for about 50 to 60 percent of the increase in age-adjusted survival rates in the first 6…  
  • A prostate cancer vaccine, sipleucel-T immunotherapy, in men with metastatic castration-resistant prostate cancer, reduced the risk of death by 22 percent compared to placebo, and represented a 4.2 month improvement in…  
  • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets CA125, a surface protein, or antigen, that is released in excess quantities by some ovarian cancers.…  
  • A 2002 study found that image-guided percutaneous needle biopsies are between 3 and 7 times more cost-effective than open surgical biopsies, require a shorter procedure time, result in fewer infections,…  
  • A drug for testicular cancer that cost an estimated $56 million to develop led to a sharp increase in survival rate and an annual return of $166 million in treatment…